Industry
Biotechnology
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Loading...
Open
0.24
Mkt cap
5.1M
Volume
36K
High
0.25
P/E Ratio
0.51
52-wk high
4.31
Low
0.23
Div yield
N/A
52-wk low
0.20
Portfolio Pulse from Benzinga Insights
October 18, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
October 18, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Insights
October 17, 2024 | 12:10 pm
Portfolio Pulse from Avi Kapoor
October 17, 2024 | 9:39 am
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 8:39 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 14, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.